NF-κB peptides designed to disrupt NEMO oligomerization
The present invention relates to polypeptides that inhibit the NF-κB signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.
1. A purified polypeptide consisting of an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 3, wherein the polypeptide inhibits the NF-κB pathway by disrupting the NF-kB essential modulator (NEMO) oligomerization.
2. A polypeptide fusion construct consisting of an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 3, which is linked to a polypeptide having a high transduction potential, wherein said polypeptide fusion construct inhibits the NF-κB pathway by disrupting NEMO oligomerization.
3. The polypeptide of claim 2 , wherein said polypeptide is linked by an amino acid spacer sequence, wherein said amino acid spacer sequence is selected from the group consisting of SEQ ID NO: 40 and SEQ ID NO: 41.
4. The polypeptide of claim 2 , wherein said polypeptide having a high transduction potential has the amino acid sequence of SEQ ID NO: 1.
5. A purified polypeptide consisting of an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 14 wherein the polypeptide inhibits the NF-κB pathway by disrupting NEMO oligomerization.
6. A polypeptide fusion construct consisting of an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 14, which is linked to a polypeptide having a high transduction potential, wherein said polypeptide fusion construct inhibits the NF-κB pathway by disrupting NEMO oligomerization.
7. The polypeptide of claim 6 , wherein said polypeptide is linked by an amino acid spacer sequence, wherein said amino acid spacer sequence is selected from the group consisting of SEQ ID NO: 40 and SEQ ID NO: 41.
8. The polypeptide of claim 6 , wherein said polypeptide having a high transduction potential has the amino acid sequence of SEQ ID NO: 1.